NCT00126503 - Sorafenib Tosylate and Bevacizumab in Treating Patients With Advanced Kidney Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 31, 2005

Primary Completion Date

October 31, 2011

Study Completion Date

February 29, 2012

Conditions

Chromophobe Renal Cell CarcinomaClear Cell Renal Cell CarcinomaPapillary Renal Cell CarcinomaRecurrent Renal Cell CarcinomaSarcomatoid Renal Cell CarcinomaStage IV Renal Cell Cancer

Interventions

BIOLOGICAL

Bevacizumab

Given IV

DRUG

Sorafenib Tosylate

Given PO

OTHER

Pharmacological Study

Correlative studies

OTHER

Laboratory Biomarker Analysis

Correlative studies

Trial Locations (5)

19104

University of Pennsylvania/Abramson Cancer Center, Philadelphia

37232

Vanderbilt-Ingram Cancer Center, Nashville

02115

Dana-Farber Cancer Institute, Boston

Dana-Farber Harvard Cancer Center, Boston

02215

Beth Israel Deaconess Medical Center, Boston

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH